Buy Evrenzo (Roxadustat) Online For Sale
DISEASE INDICATIONS: Anemia
MANUFACTURER: Astellas Pharma Inc. FibroGen
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Pharmaceuticals and Medical Devices Agency (PMDA)
Evrenzo (roxadustat) is a medication used to treat anemia in patients with chronic kidney disease (CKD), with a reduction in RBCs and hemoglobin levels.
Evrenzo (Roxadustat) is a medication used to treat anemia in patients with chronic kidney disease (CKD). Anemia is a common complication in CKD, characterized by a decrease in the number of red blood cells and hemoglobin, which carries oxygen throughout the body. Evrenzo is effective in both dialysis-dependent and non-dialysis dependent patients.
Evrenzo works by stimulating the production of erythropoietin (EPO), a hormone produced by the kidneys that regulates red blood cell production. In patients with CKD, EPO production decreases, leading to anemia. Evrenzo mimics the effects of EPO, stimulating the bone marrow to produce more red blood cells and hemoglobin.
Evrenzo is taken orally, usually once a day, with or without food. The dose is based on the patient’s weight and hemoglobin level. Evrenzo may take several weeks to take effect, and the dose may need to be adjusted based on the patient’s response and any side effects experienced. Common side effects of Evrenzo include nausea, vomiting, and diarrhea. In addition, Evrenzo may increase blood pressure and the risk of blood clots.
Clinical studies have shown the efficacy and safety of Evrenzo in the treatment of anemia associated with CKD. In a study of dialysis-dependent patients, Evrenzo was found to be non-inferior to epoetin alfa, a commonly used medication for anemia in CKD. In addition, Evrenzo was found to be effective in non-dialysis dependent patients, with a significant increase in hemoglobin levels compared to placebo.
Evrenzo represents an important treatment option for patients with anemia associated with CKD. It offers a targeted approach to stimulating red blood cell production and improving hemoglobin levels, potentially improving physical function and quality of life. Healthcare providers should monitor patients closely for any side effects or changes in blood pressure or clotting while taking Evrenzo. In addition, patients should inform their providers of any other medications or supplements they are taking.
In conclusion, Evrenzo is an effective medication used for the treatment of anemia associated with chronic kidney disease, in both dialysis-dependent and non-dialysis dependent patients. By stimulating erythropoietin production, it can improve red blood cell production and hemoglobin levels, potentially improving physical function and quality of life. Although it may cause side effects, healthcare providers can monitor patients closely and make dose adjustments accordingly. For patients with CKD and anemia, Evrenzo represents a new hope for improved symptom management and overall health.
30 tablets of 20 mg, 12 tablets of 20 mg, 12 tablets of 50 mg, 30 tablets of 50 mg, 30 tablets of 100 mg